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BACKGROUND: The prevalence of ischemic heart disease (IHD) in women of child-bearing age is rising. Data on pregnancies 
however are scarce. The objective is to describe the pregnancy outcomes in these women.
METHODS AND RESULTS: The European Society of Cardiology-EURObservational Research Programme ROPAC (Registry of 
Pregnancy and Cardiac Disease) is a prospective registry in which data on pregnancies in women with heart disease were 
collected from 138 centers in 53 countries. Pregnant women with preexistent and pregnancy-onset IHD were included. 
Primary end point were maternal cardiac events. Secondary end points were obstetric and fetal complications. There were 
117 women with IHD, of which 104 had preexisting IHD. Median age was 35.5 years and 17.1% of women were smoking. There 
was no maternal mortality, heart failure occurred in 5 pregnancies (4.8%). Of the 104 women with preexisting IHD, 11 women 
suffered from acute coronary syndrome during pregnancy. ST-segment‒elevation myocardial infarction were more common 
than non‒ST-segment‒elevation myocardial infarction, and atherosclerosis was the most common etiology. Women who had 
undergone revascularization before pregnancy did not have less events than women who had not. There were 13 women with 
pregnancy-onset IHD, in whom non‒ST-segment‒elevation myocardial infarction was the most common. Smoking during 
pregnancy was associated with acute coronary syndrome. Caesarean section was the primary mode of delivery (55.8% in 
preexisting IHD, 84.6% in pregnancy-onset IHD) and there were high rates of preterm births (20.2% and 38.5%, respectively).
CONCLUSIONS: Women with IHD tolerate pregnancy relatively well, however there is a high rate of ischemic events and these 
women should therefore be considered moderate- to high-risk. Ongoing cigarette smoking is associated with acute coronary 
syndrome during pregnancy.
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Maternal heart disease is an important cause of maternal mortality worldwide and is in fact the number 1 cause of maternal mortality in western countries.
1 From the 2016 Confidential Enquiry into ma-
ternal deaths in the United Kingdom, it is known that 
ischemic heart disease (IHD) and myocardial infarction 
Correspondence to: Jolien W. Roos-Hesselink, MD, PhD, Department of Cardiology, Erasmus Medical Center, P.O. Box: 2040, 3000 CA Rotterdam, The 
Netherlands. E-mail: j.roos@erasmusmc.nl
Supplementary Materials for this article are available at https://www.ahajo urnals.org/doi/suppl/ 10.1161/JAHA.119.015490
*A complete list of the ROPAC Investigators Group members can be found in the Supplemental Material.
For Sources of Funding and Disclosures, see page 8.
© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.  This is an open access article under the terms of the Creative 
Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and 
is not used for commercial purposes. 




 http://ahajournals.org by on A
ugust 19, 2020
J Am Heart Assoc. 2020;9:e015490. DOI: 10.1161/JAHA.119.015490 2
Baris et al IHD in Pregnancy—Data From ROPAC
during pregnancy are the most important contributors 
to maternal mortality from cardiac disease.2 In preg-
nant women, there is a 3- to 4-fold increase in risk of 
myocardial infarction compared with age-matched 
non-pregnant women of comparable age.3 With the 
trend of delaying motherhood to an older age, the asso-
ciated rise in traditional risk factors for atherosclerosis 
such as obesity, and an ongoing prevalence of ciga-
rette smoking, the burden of IHD in women of child-
bearing age is expected to increase. Coronary events 
during pregnancy however are not solely attributable 
to an atherosclerotic substrate. There are several other 
pathophysiological mechanisms that are generally less 
common or equally or more prevalent during preg-
nancy, such as pregnancy-associated spontaneous 
coronary artery dissection, coronary spasms, and cor-
onary thrombi. Data on maternal and fetal pregnancy 
outcomes in women with IHD are scarce and current 
evidence is mostly based on small retrospective stud-
ies and expert opinion. The purpose of this study is 
to describe the cardiovascular, obstetric and fetal out-
comes of pregnancy in a prospective cohort of women 
with ischemic heart disease, and to identify predictors 
of acute coronary syndrome (ACS) during pregnancy.
METHODS
Study Design
The ROPAC (Registry on Pregnancy and Cardiac 
Disease) from EURObservational Research Programme 
(EORP) of the European Society of Cardiology (ESC), is 
a worldwide, prospective registry of pregnant women 
with heart disease. Study design and methods have 
been described in detail previously.4 All national socie-
ties of the ESC were informed and invited to contact 
centers in their countries dealing with pregnancy and 
heart disease. In addition, other centers that were in-
terested in the registry were invited to participate. All 
participating centers had Medical Ethical Committee 
approval and all participating patients signed informed 
consent forms. The data that support the findings of 
this study are available from the corresponding au-
thor upon reasonable request. Pregnant women were 
included from 2007 up to 2018. For this analysis, all 
pregnancies in women with preexisting IHD before 
pregnancy and with ACS during pregnancy were in-
cluded. Thus, multiple pregnancies in one woman 
could be included. Because of the anonymized nature 
of the database it is not possible to check whether 
multiple pregnancies in one woman were included. 
Therefore, in ROPAC, each pregnancy is considered 
an individual patient.
Definitions and End Points
The primary end point was the occurrence of a ma-
ternal cardiac event during pregnancy up to 6 months 
post-partum and included maternal mortality, heart 
failure, atrial fibrillation or flutter, ventricular tachyar-
rhythmias, endocarditis, thromboembolic events and, 
in the women with preexistent IHD, the occurrence 
of ACS during pregnancy. Prior IHD was defined as 
either based on prior coronary angiography, ECG 
changes consistent with ischemia or prior episodes of 
complaints with elevated troponin levels. ACS was de-
fined according to the ESC Guidelines.5–7 Secondary 
end points were obstetric outcome (major post-par-
tum hemorrhage, caesarean section and emergency 
caesarean section, preeclampsia and eclampsia and 
CLINICAL PERSPECTIVE
What Is New?
• To our knowledge, this is the largest prospec-
tive study to date on pregnancy in women with 
ischemic heart disease. We discovered that 
women with ischemic heart disease are sig-
nificantly older, more often smoker and diabetic 
and more hypertensive and overweight than 
women without ischemic heart disease, and 
that smoking during pregnancy is predictive of 
the occurrence of new ischemic events during 
pregnancy.
What Are the Clinical Implications?
• By identifying these risk factors, pre-pregnancy 
counseling and management during pregnancy 
of women at risk, can be done more evidence-
based and individually focused.
Nonstandard Abbreviations and Acronyms
ACS acute coronary syndrome
CS caesarean section
EORP EURObservational Research 
Programme
ESC European Society of Cardiology
HELLP hemolysis, elevated liver enzymes and 
low platelets
IHD ischemic heart disease
NSTEMI non‒ST-segment‒elevation myocardial 
infarction
ROPAC Registry Of Pregnancy And Cardiac 
disease
SCAD spontaneous coronary artery dissection
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pregnancy-induced hypertension) and fetal outcome 
(prematurity, fetal mortality, neonatal mortality, intra-
uterine growth restriction, low birth weight and low 
Apgar score). Heart failure was defined according to 
the ESC guidelines8 and heart failure episodes were 
only included when they required hospital admission, 
new treatment or change in existing treatment regimen. 
Impaired left ventricular function was defined as a left 
ventricular ejection fraction of <40%. Postpartum hem-
orrhage was defined as increased blood loss (>500 mL 
after vaginal delivery or >1000  mL after caesarean 
delivery) directly after delivery and up until 24  hours 
postpartum. Pregnancy-induced hypertension, (pre-)
eclampsia and hemolysis, elevated liver enzymes and 
low platelet-syndrome were defined according to the 
International Society for the Study of Hypertension in 
Pregnancy 2012 statement.9 Fetal mortality was de-
fined as the death of a fetus after 24 weeks of gestation 
up until before birth. Neonatal mortality was defined as 
the death of a live-born baby within the first 6 months 
of life. Premature birth was defined as birth before 
37 weeks of gestation. Low birth weight was defined 
as a birth weight of <2500 g. Low Apgar score was de-
fined as an Apgar score at 5 minutes of <7. All primary 
and secondary outcomes occurring during pregnancy 
and up to 6 months post-partum were included.
Data
The ROPAC study protocol and the first results of this 
registry were published in 20134 and the results of the 
complete registry were published in 2019.10 Baseline 
characteristics collected before pregnancy included 
age, New York Heart Association functional classifi-
cation, ECG rhythm, diagnosis, risk factors (smoking 
habits, hypertension, diabetes mellitus), medication, 
previous interventions, parity and obstetric history 
and echocardiographic measurements. Countries 
were divided into developed or emerging coun-
tries according to the International Monetary Fund 
Classification. Twin pregnancies were included as 
one pregnancy.
Statistical Analysis
Numerical data are presented as mean values and 
SD or median with range depending on normality. 
Categorical data are presented as frequencies and 
percentages. Univariable analyses to identify base-
line characteristics associated with ACS during preg-
nancy were performed with Chi-square tests, Fisher 
exact tests, Student t-tests or Mann–Whitney U tests 
as appropriate. Variables with P<0.05 in the univari-
able analysis were used in a multivariable logistic re-
gression analysis to identify independent predictors 
of ACS during pregnancy. Missing values were han-
dled with multiple imputation, as described in Data 
S1. A P value of <0.05 (2-sided test) was considered 
significant. All statistical tests and analyses were per-
formed with SPSS version 21.0 and 25.0 (SPSS Inc., 
Chicago).
RESULTS
Of the 5739 pregnancies in ROPAC, 104 pregnancies 
in women with preexisting IHD and 13 in women in 
whom IHD was first diagnosed in pregnancy (a total of 
117 pregnancies in women with IHD) were included in 
this study. Median age was 35.5 years and in 25.6% 
of pregnancies women were nulliparous. Median body 
mass index was 27.1 and 17.1% of women were smok-
ing during pregnancy. The baseline characteristics for 
the total IHD group and specified for the preexisting 
and pregnancy-onset groups are shown in Table 1. Of 
the 104 pregnancies in women with preexisting IHD, 73 
(70.2%) women had undergone a coronary intervention 
before pregnancy: in 60 this was a percutaneous coro-
nary intervention, in 9 a coronary artery bypass graft-
ing and in 4 both percutaneous coronary intervention 
and coronary artery bypass grafting. The severity of 
the preexisting IHD is shown in Figure S1. The majority 
of patients suffered from single-vessel disease (43%). 
Table 1 also shows the baseline characteristics of the 
IHD group compared with the non-IHD patients within 
ROPAC. Women with IHD were significantly older, had 
higher body mass index, higher incidences of hyper-
tension, diabetes mellitus, and were more often smok-
ing. A total of 24 women suffered from ACS during or 
after pregnancy, 1 in the first trimester, 1 in the sec-
ond trimester, 21 in the third trimester, and 1 8 weeks 
post-partum.
Preexisting IHD: Maternal Outcome, 
Pathophysiology, Predictors, and 
Treatment
There were no cases of maternal mortality, while heart 
failure complicated 5 pregnancies (4.8%), see Table 2. 
Of the 5 women who suffered from heart failure, only 
2 had impaired left ventricular function before preg-
nancy, while the other 3 concomitantly suffered from 
ACS during pregnancy. In 11 of the 104 women (10.6%) 
an ACS occurred during the current pregnancy, 8 had 
an ST-segment‒elevation myocardial infarction (STEMI) 
and 3 a non‒ST-segment‒elevation myocardial infarc-
tion (NSTEMI). Of the 11 women with ACS during preg-
nancy, there were 5 cases of primary atherosclerosis 
(of which 3 also had a thrombus), 3 cases with a pri-
mary thrombus without atherosclerotic disease and 3 
patients with a spontaneous coronary artery dissec-
tion (SCAD). In Table S1, the treatment regimens for the 
ACS in women with preexisting IHD are shown for the 
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coronary interventions were performed (7 for STEMI 
and 2 for NSTEMI), 1 patient underwent a coronary 
artery bypass grafting for STEMI and 1 NSTEMI was 
treated conservatively. Table 2 shows the most impor-
tant cardiovascular events in women with preexisting 
IHD comparing women who underwent prior coronary 
interventions and women who did not. There were no 
significant differences between the 2 groups. Figure 1 
shows the results of the univariable logistic regres-
sion analysis in women with preexisting IHD. In these 
women, smoking during pregnancy is significantly as-
sociated with new ACS during pregnancy.
Pregnancy-Onset ACS: Maternal 
Outcome, Pathophysiology and Treatment
Of the 13 women with a pregnancy-onset coronary 
event that did not have preexisting IHD, there were no 
cases of maternal mortality, but 1 woman suffered from 
heart failure during pregnancy, as shown in Table 3. Of 
Table 1. Baseline Characteristics of the Total IHD Group Compared With the Rest of the ROPAC Cohort Without IHD, and 









Onset IHD (n=13) P Value
Demographics
Age, y (median, range) 35.5 (18–49) 29.3 (18–52) <0.001 35.5 (18–49) 38.1 (23–49) 0.73
Nulliparity 30 (25.6%) 2543 (45.2%) <0.001 28 (26.9%) 2 (15.4%) 0.37
BMI in kg/m2 (median, range) 21.7 (18.3–41.7) 23.9 (14.3–47.8) <0.001 26.8 (18.3–40.7) 28.1 (23.9–41.7) 0.97
Emerging country 43 (36.8%) 2238 (39.8%) 0.33 36 (34.6%) 7 (53.8%) 0.68
Pre-pregnancy characteristics
Non-smoker 68 (58.1%) 4186 (74.5%) <0.001 60 (57.7%) 8 (61.5%) 0.29
Former smoker 16 (13.7%) 426 (7.6%) 0.01 13 (12.5%) 3 (23.1%) 0.29
Current smoker 20 (17.1%) 208 (3.7%) 0.01 20 (19.2%) 2 (15.4%) 0.22
Hypertension 32 (27.4%) 348 (6.2%) <0.001 28 (26.9%) 4 (30.8%) 0.76
Atrial fibrillation 0 (0%) 106 (1.9%) 0.134 0 (0%) 0 (0%) n.a.
Signs of heart failure 18 (15.4%) 578 (10.3%) 0.18 15 (14.4%) 3 (23.1%) 0.01
Diabetes mellitus 18 (15.4%) 72 (1.3%) <0.001 16 (15.4%) 2 (15.4%) 0.54
History of NSTEMI 19 (16.2%) 0 (0%) n.a. 19 (18.3%) 0 (0%) n.a.
History of STEMI 26 (22.2%) 0 (0%) n.a. 26 (25.0%) 0 (0%) n.a.
History of CABG 13 (11.1%) 0 (0%) n.a. 13 (12.5%) 0 (0%) n.a.
History of PCI 64 (54.7%) 0 (0%) n.a. 64 (61.5%) 0 (0%) n.a.
History of angina pectoris without 
NSTEMI/STEMI
25 (21.4%) 0 (0%) n.a. 25 (24.0%) 0 (0%) n.a.
LVEF <40% 15 (12.8%) 289 (5.1%) <0.001 13 (12.5%) 2 (15.4%) 0.69
Cardiac medication use 57 (48.7%) 1990 (35.4%) <0.001 72 (69.2%) 7 (53.8%) 0.26
Beta blocker 21 (17.9%) 425 (7.6%) <0.001 20 (19.2%) 1 (7.7%) 0.31
ACE-inhibitor 11 (9.4%) 66 (1.2%) <0.001 11 (10.6%) 0 (0%) 0.001
Diuretics 2 (1.7%) 46 (0.8%) 0.42 2 (1.9%) 0 (0%) 0.35
Anti-platelet therapy* 39 (33.3%) 195 (3.5%) <0.001 38 (36.5%) 1 (7.7%) 0.04
VKA 3 (2.6%) 393 (7.0%) 0.06 3 (2.9%) 0 (0%) 0.54
NYHA class† 0.15
NYHA class I 83 (70.9%) 4124 (73.4%) 0.56 76 (73.1%) 7 (53.8%)
NYHA class II 23 (19.7%) 1168 (20.8%) 0.77 21 (20.2%) 2 (15.4%)
NYHA class III 7 (6.0%) 169 (3.0%) 0.07 4 (3.8%) 3 (23.1%)
P values were calculated between the women with IHD to the rest of the ROPAC cohort and between the preexisting and the pregnancy-onset IHD group 
with Chi-square tests and Mann–Whitney U tests where appropriate. ACE indicates angiotensin-converting enzyme; BMI, body mass index; CABG, coronary 
artery bypass grafting; LVEF, left ventricular ejection fraction; IHD, ischemic heart disease; n.a., indicates not applicable; NSTEMI, non‒ST-segment‒elevation 
myocardial infarction; NYHA, New York Health Association; PCI, percutaneous coronary intervention; ROPAC, Registry of Pregnancy and Cardiac Disease; 
STEMI, ST-segment‒elevation myocardial infarction; and VKA, Vitamin K antagonist.
*Antiplatelet therapy includes aspirin, ticagrelor, prasugrel, and clopidogrel.
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the 13 women with ACS, 3 suffered from STEMI and 
6 from NSTEMI, all during pregnancy. There were 3 
women with unstable angina pectoris and in 1 woman 
the type of ACS was unknown. There were 2 cases of 
SCAD (1 STEMI and 1 NSTEMI), in 4 women there was 
underlying atherosclerotic disease (of which 2 with a 
thrombus and 1 of which was a STEMI), one woman 
suffered from coronary spasm (NSTEMI) and 1 from 
an isolated coronary thrombus (NSTEMI). In 5 women 
no coronary angiography was performed and thus no 
clear cause was defined. In Figure 2 the distribution of 
the different types of ACS is shown and in Table S1, the 
treatment regimens for the ACS in women with preg-
nancy-onset IHD are shown for the different pathological 
mechanisms. Six percutaneous coronary interventions 
were performed, of which 1 was for an SCAD (STEMI).
Obstetric and Fetal Outcome
The obstetric and fetal outcomes are summarized in 
Table  3. Gestational hypertension and (pre-)eclamp-
sia occurred in respectively 5.8% and 4.8% of women. 
There were high rates of deliveries by caesarean section 
(55.8% in preexisting IHD and 84.6% in pregnancy-on-
set IHD) and high rates of preterm births (20.2% in pre-
existing IHD and 38.5% in pregnancy-onset IHD). Three 
neonates died within 6 months after birth, all of whom 
were born prematurely and of whom 1 had trisomy 18.
Medication During Pregnancy
Table S2 shows the cardiac medication use before 
and during pregnancy. There were 26 women who 














Intervention (n=31) P Value
Maternal mortality 0 (0%) 0 (0%) 0 (0%) n.a. 0 (0%) 0 (0%) n.a.
Hospital admission for cardiac 
reasons
26 (22.2%) 16 (15.4%) 10 (76.9%) <0.001 11 (15.1%) 15 (34.1%) 0.02
Acute coronary syndrome 24 (20.5%) 11 (10.6 %) 13 (100%) <0.001 9 (17.0%) 2 (6.5%) 0.17
Heart failure during pregnancy 6 (5.1%) 5 (4.8%) 1 (7.7%) 0.66 4 (5.5%) 2 (4.5%) 0.82
Heart failure post-partum 1 (0.9%) 1 (1.0%) 0 (0%) 0.54 3 (4.1%) 0 (0%) 0.17
Atrial fibrillation or flutter 0 (0%) 0 (0%) 0 (0%) n.a. 0 (0%) 0 (0%) n.a.
Ventricular tachyarrhythmias 2 (1.7%) 1 (1.0%) 1 (7.7%) 0.08 1 (1.9%) 0 (0%) 0.44
Thrombo-embolic events 1 (0.9%) 1 (1.0%) 0 (0%) 0.72 1 (1.9%) 0 (0%) 0.44
P values were calculated using Chi-square tests between pregnancy-onset ischemic heart disease and preexisting ischemic heart disease and between 
women who have undergone prior coronary interventions and women who have not. IHD indicates ischemic heart disease.
Figure 1. Results of the univariable logistic regression analysis, 
identifying predictors of acute coronary syndrome in pregnancy 
in women with preexisting ischemic heart disease (n=104).
Age was divided into ordinal categories defined as <25, 25 to 
34, 35 to 44 and ≥45 years, with age <25 years as the reference 
category. Smoking was defined as current smoking with 
reference category former and never smoking. Lower Limit=95% 
CI lower limit, upper Limit=95% CI upper limit. BMI indicates 
body mass index; and OR, odds ratio.
Table 3. Obstetric and Fetal Outcomes







Fetal mortality 1 (1.0%) 0 (0%) 1.00
Neonatal mortality 2 (1.9%) 1 (7.7%) 0.30
Congenital heart disease 2 (1.9%) 0 (0%) 1.00
Other congenital disease 5 (4.8%) 0 (0%) 1.00
Pregnancy-induced 
hypertension
6 (5.8%) 0 (0%) 1.00
HELLP or (pre-)eclampsia 5 (4.8%) 0 (0%) 1.00
Caesarean section 58 (55.8%) 11 (84.6%) 0.053
Emergency caesarean 5 (4.8%) 1 (7.7%) 0.42
For cardiac reasons 2 (1.9%) 1 (7.7%) 0.30
Post-partum hemorrhage 5 (4.8%) 2 (15.4%) 0.17
Preterm delivery 21 (20.2%) 5 (38.5%) 0.15
Low Apgar score 9 (8.7%) 1 (7.7%) 1.00
Low birth weight 11 (10.6%) 3 (23.1%) 0.06
IUGR 8 (7.7%) 2 (15.4%) 0.31
P values were calculated using Fisher exact tests. HELLP indicates 
hemolysis, elevated liver enzymes and low platelets; IHD, ischemic heart 
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were using statins before pregnancy (22.2%), of which 
9 continued during pregnancy and 1 woman newly 
started statins during pregnancy. The risk of structural 
congenital anomalies in the newborns of women using 
statins (P=0.99), antiplatelet therapy (P=0.50) and beta 
blockers (P=0.99) during pregnancy was not differ-
ent compared with those not on these medications. 
Between women who were using beta-blockers during 
pregnancy and women who were not, the incidences 
of intra-uterine growth restriction (P=0.79) and low birth 
weight (P=0.98) were not significantly different.
DISCUSSION
To our knowledge, this is the largest prospective study to 
date on pregnancy outcomes in women with preexisting 
and pregnancy-onset IHD. In women with preexisting 
IHD, no maternal mortality occurred and the incidence 
of ACS during subsequent pregnancy was 10.6%. 
Women with IHD were older and had more often co-
morbidities. Smoking during pregnancy was associated 
with the occurrence of ACS during  pregnancy in women 
with known IHD. Also, no maternal mortality occurred in 
the women with pregnancy-onset IHD. Rates of deliver-
ies by caesarean section were extremely high, especially 
in the group with  pregnancy-onset IHD (84.6%).
Maternal Cardiovascular Outcome
There were no maternal deaths in our study. The 5% 
heart failure rate suggest that the majority of women 
with preexisting IHD coped well with the increased 
cardiovascular demands induced by pregnancy. In 
104 women with preexisting IHD, an ACS occurred 
during pregnancy in 11 (10.6%). This is in accord-
ance with a recent systematic review by Lameijer et 
al on pregnancy outcomes in 124 pregnancies in 116 
women with preexistent IHD, in which authors found 
a coronary ischemic event rate of 9%.11 According 
to the guideline definition of ACS, we have included 
unstable angina pectoris in our study as a coronary 
ischemic event, which could explain why our inci-
dence of ACS is slightly higher than that found in 
the systematic review, although this might not be a 
significant difference In accordance with the current 
literature, the vast majority of women suffered from 
ACS in the third trimester.12,13 Possibly the increase in 
cardiac output during pregnancy gradually increases 
the myocardial oxygen demand, peaking in the third 
trimester.14 Also, the integrity and constitution of the 
coronary artery wall may be affected by hormonal 
alterations in the last stages of pregnancy, leading 
to changes in collagen and thus an increased risk of 
coronary dissection.12
Maternal smoking status seems to be import-
ant for predicting the ACS risk during pregnancy in 
women with preexisting IHD. While former smoking 
was not a predictor of ACS in our study, smoking 
during pregnancy was most strongly associated with 
the occurrence of ACS in women with preexisting 
IHD. Elkayam et al15 also found this cardiovascu-
lar risk factor to be common in women with acute 
Figure 2. Distribution and pathophysiology of the different types of acute coronary 
syndrome during pregnancy.
NSTEMI indicates non‒ST-segment‒elevation myocardial infarction; SCAD, spontaneous 
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myocardial infarctions during pregnancy. Ladner et 
al12 found that chronic hypertension, diabetes mel-
litus, advanced maternal age, and (pre-)eclampsia 
were additional independent risk factors for ACS 
during pregnancy.
Of the 24 cases of ACS in our study, 55% were 
STEMI and 45% NSTEMI. Elkayam et al15 also found 
that during pregnancy, STEMI is more common than 
NSTEMI. Furthermore, coronary atherosclerosis was 
the most common pathophysiological basis of ACS 
during pregnancy in our study (39%), a finding that is 
consistent with the literature.11,16 It is notable however, 
that the women who had undergone pre-pregnancy 
coronary revascularization did not have significantly dif-
ferent outcome than those who had not. Lameijer et al11 
also found that revascularization therapy pre-pregnancy 
did not influence the primary end point of ischemic car-
diovascular events. These findings are in relative con-
tradiction to the current ESC guideline,3 in which it is 
stated that women with prior IHD and residual ischemia 
should be discouraged from having subsequent preg-
nancies. Unfortunately, in our study the pathology of the 
ischemic events that women suffered before pregnancy 
is not known (ie, SCAD, coronary spasm, atheroscle-
rotic disease). It can of course be that the women who 
were not revascularized before pregnancy, were those 
without an underlying atherosclerotic substrate and 
thus had no residual ischemia to begin with, or that they 
had less severe disease. Further studies are needed 
to assess the need for revascularization before preg-
nancy, especially when the underlying coronary artery 
disease is non-atherosclerotic. Of course, when there 
is detectable ischemia, this should evidently be treated 
before embarking upon a pregnancy.
Mortality rates in women with preexisting IHD vary 
in the literature, with reported incidences between 0% 
and 23%.3 From the 2016 Confidential Enquiry into 
maternal deaths in the United Kingdom, we know that 
IHD and ACS during pregnancy are the most important 
contributors to maternal mortality from heart disease.2 
We found no maternal deaths in our study, neither in 
the women with preexisting IHD nor in women with 
pregnancy-onset IHD.
Obstetric and Fetal Outcome
In our study, there were high rates of Caesarean 
section (CS) (55.8% in preexisting IHD and 84.6% in 
pregnancy-onset IHD) and high rates of premature 
births (20.2% and 38.5%, respectively) compared with 
healthy pregnancy. Lameijer et al13 also reported an 
overall caesarean section rate of 57%, with a rate of 
62% for women with pregnancy-onset IHD. These 
rates are more than twice as high as the CS rate in 
Europe.17 Burchill et al18 showed a lower CS rate (38%) 
in women with preexiting IHD.
The most likely explanation for the high rates of 
premature birth in our study is that it is iatrogenic 
and secondary to CS. Especially in the case of a 
cardiovascular event, a CS seems like the most sta-
ble and controlled situation for (immediate) delivery. 
From an earlier ROPAC analysis on mode of delivery 
however, we know that a planned CS in general does 
not improve maternal or fetal outcome in women 
with stable heart disease. In women with preexisting 
IHD without recent coronary events and with good 
cardiac function, vaginal delivery thus has important 
and prevailing benefits for both mother and child. The 
hemodynamic stress of labor and delivery can be 
attenuated by epidural anesthesia and assisted in-
strumental delivery. Planned CS should be reserved 
for obstetric indications only with some extremely 
high-risk cardiac exceptions in which the prolonged 
stress of labor forms a risk for the maternal and neo-
natal well-being, ie, after a recent ischemic event or 
in women with reduced left ventricular function.3,19 
After maternal stabilization after ACS, it is advisable 
when possible to delay the delivery for a few weeks, 
to reduce the need for a high cardiac output state 
immediately after the event.3,16 In our study we found 
no relationship between maternal medication use 
during pregnancy and congenital abnormalities in the 
children, albeit our sample size is not big enough to 
support this claim. Optimal medical therapy remains 
unclear however, and further research in this field is 
warranted.
Future Perspectives and Clinical 
Implications
In comparison with the non-IHD part of the ROPAC 
cohort, women with IHD were significantly older, 
more overweight, more often smoking, hypertensive, 
diabetic, and were significantly more often multipa-
rous. This highlights the importance of pre-preg-
nancy counseling and professional help with smoking 
cessation therapy in these women. It is known that 
the risk of cardiac death during pregnancy or in the 
post-partum period is strongly related to age, being 
4 times higher in women aged >40  years.2 Also, 
multiparity could be a contributing factor to adverse 
pregnancy outcome. Any woman of advanced age 
and with additional traditional cardiovascular risk fac-
tors, who wishes to become pregnant, should thus 
be counseled about the associated risks. Needless 
to say, smoking during pregnancy should be strongly 
discouraged at all times, to improve both maternal 
and neonatal outcome, and smoking cessation ther-
apy should be an integral part of the pre-concep-
tional counseling of such women.
In our study, pre-pregnancy revascularization ther-
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ACS. This can be because of selection bias of more 
severely affected patients undergoing revascularization 
and possibly be explained by the inclusion of women 
with prior SCAD or coronary spasm for which they did 
not need to undergo revascularization therapy, there-
fore our data do not permit to refute the current rec-
ommendation that in women with preexistent IHD and 
residual ischemia, subsequent pregnancies should be 
discouraged.3
In the most recent modified World Health 
Organization classification for maternal cardiovascu-
lar risk during pregnancy, IHD as a diagnosis is not 
included.3 With ACS rate of 10.6% and concomitant 
heart failure rate of 4.8%, it seems defendable to, 
based on our results, consider women with preexis-
tent IHD as modified World Health Organization II-III. 
This means that, apart from the need for pre-concep-
tional investigation, including assessment of ventricu-
lar function and signs of residual ischemia followed by 
counseling, pregnancies in these women should be 
managed in referral hospitals with bi-monthly follow-up 
and women should be alerted to the symptoms of ACS 
and heart failure.3
Limitations
ROPAC is a registry and is therefore limited by several 
factors. Despite the prospective nature of ROPAC, 
there might still be some form of selection bias pre-
sent, as we cannot guarantee that all consecutive 
patients from all centres were included. Furthermore, 
ROPAC includes pregnancies and not patients, 
therefore it could be possible that subsequent preg-
nancies in one woman could have been included as 
2 patients. This could form a bias in the sense that it 
can be hypothesized that women who become preg-
nant more than once usually have less severe dis-
ease. Furthermore, the sample sizes in our study are 
very small, therefore the results of our study cannot 
be extrapolated to the general female IHD popula-
tion and further studies are needed in the future to 
assess pregnancy-associated risks and outcomes. 
In ROPAC, we have collected information on all con-
secutive pregnancies in women with heart disease. 
We cannot guarantee that each included pregnancy 
in ROPAC represents a different patient, as some 
women will have had multiple pregnancies over time 
included. Unfortunately, because of the anonymized 
nature of the database, we cannot track which in-
cluded pregnancies belong to the same patient, 
therefore we have decided to consider each included 
pregnancy a separate patient. This could of course 
lead to bias in favor of women with more favourable 
pregnancy outcome as women who are more seri-
ously afflicted might not embark upon a subsequent 
pregnancy. Another limitation is that we have not 
collected data on former ischemic events and have 
therefore no information on the pathophysiological 
basis of the coronary artery disease in the women 
with preexistent IHD. We have done logistic regres-
sion analyses on the maternal cardiac outcome, but 
not on the obstetric or fetal outcome. Finally, data on 
smoking before pregnancy were dichotomized, and 
thus we have no information on pack-years.
CONCLUSIONS
Compared with pregnant women without IHD, preg-
nant women with IHD are more often smoking, hy-
pertensive, overweight, and diabetic. Overall, women 
with IHD tolerate pregnancy relatively well. However, 
while there were no maternal deaths and heart failure 
rates were low, there was a high rate of ACS during 
pregnancy in our study. Ongoing cigarette smoking 
is associated with ischemic events during pregnancy 
and should strongly be discouraged. Pregnancy in 
women with ischemic heart disease should be con-
sidered moderate-to-high risk (moderate World Health 
Organization II-III) and all women with known IHD 
should undergo thorough pre-pregnancy investiga-
tions and counseling accordingly and strict follow-up 
in a referral center.
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Missing values for the following variables were imputed via multiple imputation (SPSS version 
25.0): 
Age, smoking status, BMI, parity, prior hypertension, prior diabetes, prior revascularization.  
We used a MCMC multiple imputation model as we considered the missing values to be arbitrarily 
missing. Five imputations per variable were done, and the imputed values were saved in the 
imputed dataset. Within SPSS, binary logistic regression analysis is a supported procedure within 
imputed datasets and univariate pooling was standardly used. Binary logistic regression analyses 
were done on each of the 5 imputed and the observed dataset, after which the results of each 
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ACS in pre-existing IHD  
Conservative 
treatment  
0  0  0  1  0  0  1  
Thrombolysis  0  0  0  0  0  0  0  
PCI  2  3  3  1  0  0  9  
CABG  0  0  0  1  0  0  1  
Other  0  0  0  0  0  0  0  
Total  2  3  3  3  0  0  11  
ACS in pregnancy-onset IHD  
Conservative 
treatment  
0  0  0  1  0  4  5  
Thrombolysis  0  0  0  0  0  1  1  
PCI  2  2  1  1  0  0  6  
CABG  0  0  0  0  0  0  0  
Other  0  0  0  0  1  0  1  
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Table S2. Cardiac medication use and anticoagulation during pregnancy. 
 
*Cardiac medication: all cardiac medication minus antiplatelet and anticoagulation therapy. 
 
 
 Total cohort 
(n=117) 
Pre-existing 
IHD (n=104)  
Pregnancy-onset 
IHD (n=13)  
P-value  
Cardiac medication use prior to 
pregnancy  
57 (48.7%)  72 (69.2%)  7 (53.8%)  0.26  
Beta blocker  21 (17.9%)  20 (19.2%)  1 (7.7%)  0.31  
ACE-inhibitor  11 (9.4%)  11 (10.6%)  0 (0%)  0.001  
Diuretics  2 (1.7%)  2 (1.9%)  0 (0%)  0.35  
Statins  26 (22.2%)  25 (24.0%)  1 (7.7%)  0.18  
Anti-platelet therapy  39 (33.3%)  38 (36.5%)  1 (7.7%)  0.04  
Vitamin K antagonists  3 (2.6%)  3 (2.9%)  0 (0%)  0.54  
Cardiac medication use during 
pregnancy  
41 (35.0%)  36 (34.6%)  5 (38.5%)  0.78  
Beta blocker  31 (26.5%)  28 (26.9%)  3 (23.1%)  0.77  
ACE-inhibitor  1 (0.9%)  1 (1.0%)  0 (0%)  0.72  
Diuretics  1 (0.9%)  1 (1.0%)  0 (0%)  0.72  
Statins  10 (8.5%)  9 (8.7%)  1 (7.7%)  0.91  
Anti-platelet therapy  48 (41.0%)  44 (42.3%)  4 (30.8%)  0.43  
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